As of the latest Form 4 filed Jul 2, 2026.
What Edgewise Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 35 most recent filings for EWTX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Russell Alan J Chief Scientific Officer | SSale | −69.6K | $39.41 | $2.74M | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Russell Alan J, Chief Scientific Officer | SSale | −130K | $39.41 | $5.14M | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Russell Alan J, Chief Scientific Officer | MExercise | +69.6K | $0.18 | $12.5K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Russell Alan J, Chief Scientific Officer | MExercise | +130K | $0.45 | $58.7K | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | Fox Jonathan C Director | AAward | +319.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Donovan Joanne M. CMO | SSale | −50.0K | $38.57 | $1.93M | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Donovan Joanne M., CMO | MExercise | +50.0K | $7.08 | $354K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-04 | Donovan Joanne M., CMO | SSale | −5.23K | $31.29 | $164K | No | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Fox Jonathan C Director | AAward | +339.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-31 | Donovan Joanne M. CMO | SSale | −21.3K | $32.12 | $685K | Yes (planned) | Form 4 ↗ |
| 2026-03-31 | 2026-03-31 | Donovan Joanne M., CMO | MExercise | +21.3K | $7.08 | $151K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-27 | Donovan Joanne M. CMO | SSale | −6.74K | $30.98 | $209K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-27 | Donovan Joanne M., CMO | SSale | −9.62K | $30.98 | $298K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin Director | SSale | −66.5K | $29.44 | $1.96M | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | SSale | −10.5K | $29.44 | $308K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | SSale | −7.61K | $29.44 | $224K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | SSale | −17.2K | $29.44 | $507K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | SSale | −13.7K | $29.44 | $403K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | MExercise | +7.61K | $0.71 | $5.40K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | MExercise | +66.5K | $1.93 | $128K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | MExercise | +10.5K | $1.93 | $20.2K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | MExercise | +17.2K | $0.64 | $11.0K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-21 | Edris Badreddin, Director | MExercise | +13.7K | $0.39 | $5.34K | Yes (planned) | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | MOORE JOHN R General Counsel | SSale | −1.96K | $18.91 | $37.0K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Carruthers R Michael Chief Financial Officer | SSale | −2.16K | $18.91 | $40.8K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Derakhshan Behrad Chief Business Officer | SSale | −1.72K | $18.91 | $32.5K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Russell Alan J Chief Scientific Officer | SSale | −1.58K | $18.91 | $29.8K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | Donovan Joanne M. CMO | SSale | −3.68K | $18.91 | $69.6K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-02 | KOCH KEVIN President and CEO | SSale | −3.15K | $18.91 | $59.6K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | MOORE JOHN R General Counsel | MExercise | +5.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Carruthers R Michael Chief Financial Officer | MExercise | +5.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Derakhshan Behrad Chief Business Officer | MExercise | +5.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Russell Alan J Chief Scientific Officer | MExercise | +5.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Donovan Joanne M. CMO | MExercise | +10.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | KOCH KEVIN President and CEO | MExercise | +10.4K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also EWTX’s full analysis or the market-wide insider trading feed. The tabs above jump to EWTX’s other SEC data.
Source: SEC Form 4 filings for EWTX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.